Emergent BioSolutions awarded 10-year contract valued at $535M
Emergent BioSolutions announced a contract award by the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services valued at approximately $535M over 10 years for the continued supply of Vaccinia Immune Globulin Intravenous into the U.S. Strategic National Stockpile in support of smallpox preparedness. The contract consists of a one-year base period of performance valued at $23M and nine option years that, when exercised, would bring the total contract value to approximately $535M. The scope of work under the contract includes the collection of plasma, manufacturing, and delivery of finished drug product. During year one, Emergent will use plasma provided by the U.S. government to manufacture VIGIV doses, while all subsequent years will involve Emergent-led plasma collection and production efforts resulting in higher annual revenue potential. VIGIV is the only therapeutic licensed by the FDA for the treatment of complications due to smallpox vaccination and has been stockpiled at a ratio of one dose of VIGIV per 10,000 doses of first or second generation smallpox vaccine.